Compare ADMA Biologics Inc (ADMA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Weibo Corp — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Weibo Corp trades at $7.77 (market cap $1.93B). The key difference: ADMA Biologics Inc and Weibo Corp are close in size by market cap, and Weibo Corp pays a 7.65% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WB | |
|---|---|---|
Market Cap | $2.18B | $1.93B |
Sector | Health | Media |
52-Week High | $20.38 | $12.83 |
52-Week Low | $7.60 | $7.20 |
Enterprise Value | $2.25B | $1.20B |
Dividend Yield | — | 7.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Weibo (WB) trades at $7.94, up 0.76% today, with neutral technical signals and strong fundamental metrics including a low P/E of 5.55 and robust 21.15% net income margin. Recent earnings show three consecutive quarterly misses but Q2 2026 results are pending. The company maintains solid cash flow generation with $519M operating cash flow in 2025, while analyst sentiment is mixed with 45% buy ratings.
WB presents value opportunity with discounted valuation metrics and strong profitability, though competitive pressures from Douyin and WeChat create headwinds. The stock's 8% dividend yield and cash-rich balance sheet provide downside protection, but investor sentiment remains cautious pending Q2 earnings results on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
